About Us

Nicholas Galakatos, PhD | Chairman
Dr. Nicholas Galakatos is a founder and Managing Director of Clarus, a global healthcare investment firm. He has been a venture capital investor since 1992, initially at Venrock Associates and then at MPM Capital where he was General Partner. From 1997-2000 Nick was Vice President, New Business and a member of the Management Team at Millennium Pharmaceuticals (acquired by Takeda). He was a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he also was the Chairman and founding CEO. Nick entered the venture capital business after being Head of Molecular Biology Research at Ciba (presently Novartis). He holds a B.A degree in chemistry from Reed College, a Ph.D. degree in organic chemistry from MIT, and performed postdoctoral studies in molecular biology at Harvard Medical School.  Nick is a member of the Board of Directors of Catabasis (CATB), Nanostring (NSTG), and Ophthotech (OPHT). Previously, he was the Chairman of TransForm (acquired by J&J) and Hypnion (acquired by Lilly), the Lead Director at Affymax (AFFY), and a Director of Aveo (AVEO), Caliper (CALP; acquired by Perkin-Elmer), Critical Therapeutics (CRTX), Link Medicine (acquired by AstraZeneca), Syrrx (acquired by Takeda), Millennium Predictive Medicine (acquired by Millennium), Millennium BioTherapeutics (acquired by Millennium), Portola (PTLA), and Taligen (acquired by Alexion).  Nick is a member of the Director’s Council of the Koch Institute at MIT, and the Genetics Advisory Council at Harvard Medical School.

Manos Perros, PhD | President and Chief Executive Officer
Dr. Manos Perros was central to the establishment of Entasis Therapeutics, and led talks with AstraZeneca that resulted in the creation of the new company in 2015.  Manos was Vice President of the Innovative medicines and Early Development unit of and Head of AstraZeneca’s Infection Innovative Medicines organization for more than four years, and also served as Site Head, for AstraZeneca’s Boston R&D research centre and Gatehouse Park BioHub in Waltham, MA. In his role as the Infection Head, Manos was accountable for the Infection delivery from idea to clinical proof-of-concept of a portfolio of programs against serious bacterial infections, respiratory viruses, and neglected infectious diseases (tuberculosis and malaria in particular). Manos was also the executive sponsor for the Global Chemistry Leadership team at AstraZeneca, and led the evolution of the organizational and sourcing model, including the establishment of a strategic partnership with Pharmaron (China). A chemist by training, Manos conducted his PhD work in Belgium, France and Germany, and was Associate in the Biophysics department at Yale from 1993-1995. Prior to joining AstraZeneca, Manos served as Director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as Vice-President and Chief Scientific Officer, Antivirals, at Pfizer. Manos has overseen a wide range of therapeutic areas, but his greatest contributions have been in the field of anti-infectives, where he is a distinguished and widely published scientist, having led research projects against HIV, Hepatitis C, influenza and fungal pathogens. Amongst a number of molecules still in development, Manos is a co-inventor of the first-in-class HIV treatment maraviroc (Celsentri/Selzentry) on which he worked from inception to launch. The medicine earned numerous accolades, including the 2008 Prix Galien USA. For his contributions to the discovery and development of maraviroc, Manos received the PhRMA Discoverer’s Award in 2010.

Greg Norden | Director
Greg Norden is the Managing Director of G9 Capital Group, LLC, which invests in early stage ventures and provides corporate finance advisory services. From 1989 to 2010, Mr Norden held various senior positions with Wyeth/American Home Products, most recently as Wyeth’s Senior Vice President and Chief Financial Officer. Prior to this role, Mr Norden was Executive Vice President and Chief Financial Officer of Wyeth Pharmaceuticals. Prior to his affiliation with Wyeth, Mr Norden served as Audit Manager of Arthur Andersen & Co. Mr Norden serves on the Board of Directors of NanoString, a provider of life science tools for translational research and molecular diagnostic products, Royalty Pharma, a leader in the acquisition of revenue-producing intellectual property, Univision, the leading media company serving Hispanic America, and Zoetis, the leading animal health company. Mr Norden is a former director of Welch Allyn, where he served until 2015, Lumara Health, where he served until 2014, and Human Genome Sciences, where he served until 2012.

Andy J. Staples | Director
Andy Staples is the Head of Deal Finance at AstraZeneca, having responsibility for all of the financial analysis, structuring and support for mergers and acquisitions, divestments, in- and out-licensing and strategic equity investments. During a long career at AstraZeneca, he has been involved with all stages of the pharmaceutical value chain from early stage development, through product approval and launch, to patent expiry and post LOE rationalization. Andy has also spent a lot of time working with AstraZeneca Biotech partners structuring and completing multiple deals including the acquisition of Novexel and its portfolio of novel antibiotics. He is a qualified Chartered Accountant and previously worked for PriceWaterhouseCoopers before joining AstraZeneca.

James Topper, MD, PhD | Director
Jamie is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 10 years as a General Partner, Jamie has invested across 21 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.  Jamie has led and served as a board member for many of Frazier’s successful life sciences investments, including Calistoga Pharmaceuticals (co-founder, sold to Gilead), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), Cotherix (sold to Actelion), and Threshold (NASDAQ: THLD). He currently represents Frazier on the boards of Alcresta, Allena Pharmaceuticals, Anaptys Biotech, Millendo Therapeutics (formerly Atterocor), ProNai Therapeutics (NASDAQ: DNAI), and Merganser Biotech.  Prior to joining Frazier, Jamie served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR.  Jamie received his M.D. and Ph.D. in Biophysics from Stanford University School of Medicine and holds a B.S. from the University of Michigan. He did his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women’s Hospital in Boston and is board certified in both disciplines. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. In 2011 Jamie was named to the Midas List of leading venture capitalists, and in 2013 was recognized by Forbes as one of the top 10 healthcare investors.

Peter Tuxen Bisgaard | Director
Peter Tuxen Bisgaard is a Senior Partner at Novo Ventures (US) Inc.  Peter joined Novo Ventures (US) Inc. in San Francisco, California in 2009, and Boston, Massachusetts from 2015. He is a member of the Board of Directors of Ceterix Orthopaedics Inc, Entasis, Outpost, and Ra Pharma, as well chairman of the Board of Directors of HTG Molecular Diagnostics Inc. (NASDAQ:HTG). Previously, he was, among other companies, chairman of the board of Otonomy Inc., (NASDAQ: OTIC), board member of Nevro (NASDAQ: NVRO) and Alder (NASDAQ:ALDR). From 2001-2009, Peter was employed with Novo A/S as a Partner in Novo Ventures based in Copenhagen. Prior to joining Novo A/S he was with McKinsey & Co. within the Scandinavian Corporate Finance and Strategy Group. At McKinsey, Peter focused on strategy development, mergers, acquisitions and alliances in various industries. Peter is the co-author of ‘Growth by Mergers & Acquisitions’ published by Børsens Forlag. Peter obtained an MSc in 1998 from the Technical University of Denmark and was at the same time awarded a post graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.